| May 5, 2026 | earnings | Pfizer reported Q1 2026 revenues of $14.5B and adjusted diluted EPS of $0.75, reaffirming full-year guidance. |
|---|
| Apr 27, 2026 | management_change | Shareholders elected directors, ratified auditors, and approved a stock plan at the Annual Meeting. |
|---|
| Feb 3, 2026 | earnings | Pfizer reported Q4 and full-year 2025 financial results, with $62.6 billion revenue and $3.22 adjusted EPS for 2025. |
|---|
| May 5, 2026 | Guidance: adjusted_diluted_eps | 2.80 to 3.00 |
|---|
| May 5, 2026 | Guidance: adjusted_r_d_expenses | 10.50 to 11.50 |
|---|
| May 5, 2026 | Guidance: adjusted_si_a_expenses | 12.50 to 13.50 |
|---|
| May 5, 2026 | mda_quarterly | Pfizer's first quarter 2026 total revenues increased 5% to $14.5 billion, with operational growth of 2%. This was primarily driven by strong performance from Padcev, Eliquis, Oncology biosimilars, Nurtec ODT/Vydura, Lorbrena, and Abrysvo. This growth was largely offset by significant declines in COVID-19 product revenues from Comirnaty and Paxlovid; excluding these, operational revenue growth was 7%. Income from continuing operations rose to $3.2 billion, benefiting from higher revenues and reduced restructuring charges, despite increased Cost of Sales and R&D, the latter driven by oncology and obesity pipeline investments.
Significant patent expiries are anticipated from 2026-2030, with a projected $1.5 billion revenue impact in 2026. The Inflation Reduction Act (IRA) is impacting Eliquis pricing from January 2026, with Ibrance and Xtandi affected in 2027. New U.S. Section 232 tariffs on imported patented pharmaceuticals, up to 100% duty, are set for July 2026, though Pfizer is negotiating an agreement. The company is executing cost-reduction programs, targeting $5.7 billion in savings by 2026 from "Realigning Our Cost Base" and $1.5 billion by 2027 from "Manufacturing Optimization," alongside $600 million in annual synergies from the Metsera acquisition. Recent developments include U.S. approval for Veppanu (ER+/HER2- breast cancer) and regulatory filings for Tukysa and Padcev. Pfizer maintains strong liquidity, recently exiting its ViiV investment for $1.875 billion, and prioritizes reinvestment, dividends, and future share repurchases after de-levering. |
|---|
| Feb 26, 2026 | business | Pfizer faces significant revenue concentration, with 12 products generating over $1 billion each and collectively accounting for 65% of 2025 total revenues, notably Eliquis at 13%. A substantial revenue reduction is anticipated from 2026-2030 due to patent and regulatory exclusivity expirations for several in-line products, compounded by aggressive generic "at-risk" launches and increasing biosimilar competition, which pressures pricing. Revenues from COVID-19 products like Comirnaty and Paxlovid have already decreased significantly and remain volatile.
Strategic investments include acquisitions in competitive therapeutic areas such as obesity (Metsera) and oncology (Seagen). However, high R&D costs and regulatory hurdles pose ongoing challenges to pipeline replenishment. Global operations, contributing 41% of 2025 revenues (21% from Europe, 12% from China/Japan/APAC), are subject to intense government pricing pressures. The US Inflation Reduction Act (IRA) has already selected Eliquis, Ibrance, Xtandi, and Xeljanz for Medicare price negotiation, impacting future revenues, with similar initiatives globally (e.g., EU Pharma Package, China QCE/VBP). Supply chain disruptions, product recalls (e.g., Oxbryta withdrawal), intellectual property challenges, and cybersecurity threats, including risks from AI deployment, represent additional operational and financial risks. |
|---|
